Does physical training reduce fatigue in sarcoidosis?

Sarcoidosis Vasculitis and Diffuse Lung Diseases

Volumn 32, Issue 1, 2015, Pages 53-62

  Marcellis, Rik G J ^a,b   Van Der Veeke, M A F ^c,d   Mesters, I ^d   Drent, M ^b,e   De Bie, R A ^d   De Vries, G J ^b,f   Lenssen, A F ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ild care foundation research team   (Netherlands)

^c Physiotherapy Practice FysioMedica   (Netherlands)

^d MAASTRICHT UNIVERSITY   (Netherlands)

^e MAASTRICHT UNIVERSITY   (Netherlands)

^f Department of Respiratory Medicine ORBIS MC ^*  (Netherlands)

Author keywords

Exercise capacity; Fatigue; Muscle strength; Physical training; Quality of life; Sarcoidosis

Indexed keywords

ADULT; ARTICLE; CLINICAL ARTICLE; ELBOW; EXERCISE; EXERCISE TEST; FATIGUE; FATIGUE ASSESSMENT SCALE; FEMALE; FLEXOR MUSCLE; FOLLOW UP; FUNCTIONAL STATUS ASSESSMENT; HEALTH INSURANCE; HUMAN; MALE; MEDICAL RESEARCH COUNCIL DYSPNEA SCALE; MIDDLE AGED; MUSCLE STRENGTH; PHYSICAL PARAMETERS; PRIORITY JOURNAL; QUADRICEPS FEMORIS MUSCLE; QUALITY OF LIFE; QUESTIONNAIRE; SARCOIDOSIS; SIX MINUTE WALK TEST; SUBMAXIMAL BICYCLE TEST; TRAINING; VISUAL ANALOG SCALE; WORLD HEALTH ORGANIZATION; WORLD HEALTH ORGANIZATION QUALITY OF LIFE BREF ASSESSMENT INSTRUMENT; AGE; COHORT ANALYSIS; COMPLICATION; EXERCISE TOLERANCE; KINESIOTHERAPY; LUNG FUNCTION TEST; MUSCLE WEAKNESS; NETHERLANDS; PATHOPHYSIOLOGY; PHYSIOLOGY; PILOT STUDY; PROCEDURES; PSYCHOLOGY; RISK ASSESSMENT; SARCOIDOSIS, PULMONARY; SEVERITY OF ILLNESS INDEX; SEX DIFFERENCE; TREATMENT OUTCOME; VITAL CAPACITY;

ADULT; AGE FACTORS; COHORT STUDIES; EXERCISE THERAPY; EXERCISE TOLERANCE; FATIGUE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MUSCLE WEAKNESS; NETHERLANDS; PILOT PROJECTS; QUALITY OF LIFE; RESPIRATORY FUNCTION TESTS; RISK ASSESSMENT; SARCOIDOSIS, PULMONARY; SEVERITY OF ILLNESS INDEX; SEX FACTORS; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84937578303     PISSN: 11240490     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Spruit MA, Singh SJ, Garvey C, et al. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med 2013; 188: e13-64.
2. Langer D, Hendriks E, Burtin C, et al. A clinical practice guideline for physiotherapists treating patients with chronic obstructive pulmonary disease based on a systematic review of available evidence. Clin Rehabil 2009; 23: 445-62.
3. Holland A, Hill C. Physical training for interstitial lung disease. Cochrane Database Syst Rev 2008: CD006322.
4. Huppmann P, Sczepanski B, Boensch M, et al. Effects of in-patient pulmonary rehabilitation in patients with interstitial lung disease. Eur Respir J 2013; 42: 444-53.
5. Nishiyama O, Kondoh Y, Kimura T, et al. Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. Respirology 2008; 13: 394-9.
6. Strookappe B, Elfferich MD, Swigris JJ et al. Benefits of physical training in patients with idiopathic or end-stage sarcoidosis-related pulmonary fibrosis: a pilot study. Sarcoidosis Vasc Diffuse Lung Dis 2015; In press.
7. Iannuzzi MC, Fontana JR. Sarcoidosis: clinical presentation, immunopathogenesis, and therapeutics. JAMA 2011; 305: 391-9.
8. Baughman RP, Lower EE, Gibson K. Pulmonary manifestations of sarcoidosis. Presse Med 2012; 41: e289-302.
9. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999; 160: 736-55.
10. Valeyre D, Prasse A, Nunes H, Uzunhan Y, Brillet PY, Muller-Quernheim J. Sarcoidosis. Lancet 2014; 383: 1155-67.
11. Drent M, Lower EE, De Vries J. Sarcoidosis-associated fatigue. Eur Respir J 2012; 40: 255-63.
12. Wirnsberger RM, de Vries J, Wouters EF, Drent M. Clinical presentation of sarcoidosis in The Netherlands an epidemiological study. Neth J Med 1998; 53: 53-60.
13. Marcellis RG, Lenssen AF, Elfferich MD et al. Exercise capacity, muscle strength and fatigue in sarcoidosis. Eur Respir J 2011; 38: 628-34.
14. De Kleijn WP, De Vries J, Lower EE, Elfferich MD, Baughman RP, Drent M. Fatigue in sarcoidosis: a systematic review. Curr Opin Pulm Med 2009; 15: 499-506.
15. Marcellis RGJ, Lenssen AF, Kleynen S, De Vries J, Drent M. Exercise capacity, muscle strength and fatigue in sarcoidosis: a follow-up study. Lung 2013; 191: 247-56.
16. Spruit MA, Thomeer MJ, Gosselink R, et al. Skeletal muscle weakness in patients with sarcoidosis and its relationship with exercise intolerance and reduced health status. Thorax 2005; 60: 32-8.
17. Alhamad EH. The six-minute walk test in patients with pulmonary sarcoidosis. Ann Thorac Med 2009; 4: 60-4.
18. Michielsen HJ, Drent M, Peros-Golubicic T, De Vries J. Fatigue is associated with quality of life in sarcoidosis patients. Chest 2006; 130: 989-94.
19. De Vries J, Michielsen H, Van Heck GL, Drent M. Measuring fatigue in sarcoidosis: the Fatigue Assessment Scale (FAS). Br J Health Psychol 2004; 9: 279-91.
20. Marcellis R, Lenssen A, Drent M, De Vries J. Association between physical functions and quality of life in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2014; 31: 117-28.
21. De Vries J, Wirnsberger RM. Fatigue, quality of life and health status in sarcoidosis. Eur Respir Mon 2005; 32: 92-104.
22. Baughman RP, Drent M, Culver DA et al. Endpoints for clinical trials of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2012; 29: 90-8.
23. Spruit MA, Wouters EFM, Gosselink R. Rehabilitation programmes in sarcoidosis: a multidisciplinary approach. Eur Respir J 2005; 32: 316-26.
24. Sharma OP. Fatigue in sarcoidosis: incompletely understood, inadequately treated. Curr Opin Pulm Med 2012; 18: 470-71.
25. Baughman RP, Culver DA, Judson MA. A concise review of pulmonary sarcoidosis. Am J Respir Crit Care Med 2011; 183: 573-81.
26. De Kleijn WP, De Vries J, Wijnen PA, Drent M. Minimal (clinically) important differences for the Fatigue Assessment Scale in sarcoidosis. Respir Med 2011; 105: 1388-95.
27. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report working party standardization of lung function tests, European community for steel and coal. Official statement of the European Respiratory Society. Eur Respir J Suppl 1993; 16: 5-40.
28. Michielsen HJ, De Vries J, Van Heck GL, Van de Vijver FJR, Sijtsma K. Examination of the dimensionality of fatigue: The construction of the Fatigue Assessment Scale (FAS). EJPA 2004; 20: 39-48.
29. WHO. Development of the World Health Organization WHO-QOL-BREF quality of life assessment. The WHOQOL Group. Psychol Med 1998; 28: 551-8.
30. Trompenaars FJ, Masthoff ED, Van Heck GL, Hodiamont PP, De Vries J. Content validity, construct validity, and reliability of the WHOQOL-BREF in a population of Dutch adult psychiatric outpatients. Qual Life Res 2005; 14: 151-60.
31. O'Carroll RE, Smith K, Couston M, Cossar JA, Hayes PC. A comparison of the WHOQOL-100 and the WHOQOL-BREF in detecting change in quality of life following liver transplantation. Qual Life Res 2000; 9: 121-4.
32. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999; 54: 581-6.
33. Spruit MA, Janssen DJ, Franssen FM, Wouters EF. Rehabilitation and palliative care in lung fibrosis. Respirology 2009; 14: 781-7.
34. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166: 111-7.
35. Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982; 14: 377-81.
36. Puhan MA, Mador MJ, Held U, Goldstein R, Guyatt GH, Schunemann HJ. Interpretation of treatment changes in 6-minute walk distance in patients with COPD. Eur Respir J 2008; 32: 637-43.
37. Redelmeier DA, Bayoumi AM, Goldstein RS, Guyatt GH. Interpreting small differences in functional status: the Six Minute Walk test in chronic lung disease patients. Am J Respir Crit Care Med 1997; 155: 1278-82.
38. Swigris JJ, Wamboldt FS, Behr J, et al. The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference. Thorax 2010; 65: 173-7.
39. Holland AE, Hill CJ, Conron M, Munro P, McDonald CF. Small changes in six-minute walk distance are important in diffuse parenchymal lung disease. Respir Med 2009; 103: 1430-5.
40. Du Bois RM, Weycker D, Albera C et al. Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med 2011; 183: 1231-7.
41. Verdijk LB, van Loon L, Meijer K, Savelberg HH. One-repetition maximum strength test represents a valid means to assess leg strength in vivo in humans. J Sports Sci 2009; 27: 59-68.
42. Enraf-Nonius BV. Gebruikershandleiding En-Track. Rotterdam: Enraf-Nonius B.V., 2011; 1-68.
43. Bohannon RW. Make tests and break tests of elbow flexor muscle strength. Phys Ther 1988; 68: 193-4.
44. Bohannon RW, Andrews AW. Interrater reliability of hand-held dynamometry. Phys Ther 1987; 67: 931-3.
45. Bohannon RW. Test-retest reliability of hand-held dynamometry during a single session of strength assessment. Phys Ther 1986; 66: 206-9.
46. Salhi B, Troosters T, Behaegel M, Joos G, Derom E. Effects of pulmonary rehabilitation in patients with restrictive lung diseases. Chest 2010; 137: 273-9.
47. Holland AE, Hill CJ, Conron M, Munro P, McDonald CF. Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. Thorax 2008; 63: 549-54.
48. Ozalevli S, Karaali HK, Ilgin D, Ucan ES. Effect of home-based pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. Multidiscip Respir Med 2010; 5: 31-7.
49. Kozu R, Jenkins S, Senjyu H. Effect of disability level on response to pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. Respirology 2011; 16: 1196-202.
50. Kozu R, Senjyu H, Jenkins SC, Mukae H, Sakamoto N, Kohno S. Differences in response to pulmonary rehabilitation in idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease. Respiration 2011; 81: 196-205.
51. Nishiyama O, Taniguchi H, Kondoh Y, et al. Quadriceps weakness is related to exercise capacity in idiopathic pulmonary fibrosis. Chest 2005; 127: 2028-33.
52. Spruit MA, Pitta F, Garvey C, et al. Differences in content and organisational aspects of pulmonary rehabilitation programmes. Eur Respir J 2014; 43: 1326-37.
53. Ferreira A, Garvey C, Connors GL et al. Pulmonary rehabilitation in interstitial lung disease: benefits and predictors of response. Chest 2009; 135: 442-7.